Prof. Yumei Feng, Ph.D.
Department of Biochemistry & Molecular Biology

Education

1983~1987  B.Sc., Department of Chemistry, Nankai University

1987~1990  M.Sc., Institute of Molecular Biology, Nankai University

2006~2009  Ph.D., Pharmaceutical Science and Technology, Tianjin University


Professional Experiences

1990~present Research Associate, Tianjin Medical University Cancer Institute and Hospital

2000~present  Director, Department of Biochemistry & Molecular Biology

2003~present  Professor,Tianjin Medical University Cancer Institute and Hospital

2004~2005    Visiting Scholar,University of Texas, M.D.Anderson Cancer Center


Resent Publication(*Corresponding author)

1. Wang S#, Li GX#, Tan CC#, He R#, Kang LJ#, Lu JT, Li XQ, Wang QS, Liu PF, Zhai QL, Feng YM*. FOXF2 reprograms breast cancer cells into bone metastasis seeds.Nat Commun. 2019;10(1):2707.https://academic.oup.com/annonc/article/29/4/938/4812667

2. Kang LJ#, Yu ZH#, Cai J#, He R, Lu JT, Hou C, Wang QS, Li XQ, Zhang R, Feng YM*. Reciprocal transrepression between FOXF2 and FOXQ1 controls basal-like breast cancer aggressiveness.FASEB J. 2019;33(5):6564-6573.https://www.fasebj.org/doi/abs/10.1096/fj.201801916R?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=fasebj

3. Wang QS, He R, Yang F, Kang LJ, Li XQ, Fu L, Sun B*, Feng YM*. FOXF2 deficiency permits basal-like breast cancer cells to form lymphangiogenic mimicry by enhancing the response of VEGF-C/VEGFR3 signaling pathway.Cancer Lett. 2018;420:116-126.https://www.sciencedirect.com/science/article/pii/S0304383518301022?via%3Dihub

4. Yu ZH#, Lun SM#, He R#, Tian HP, Huang HJ, Wang QS, Li XQ, Feng YM*. Dual Function of MAZ Mediated by FOXF2 in Basal-like Breast Cancer: Promotion of Proliferation and Suppression of Progression.Cancer Lett. 2017;402:142-152.https://www.sciencedirect.com/science/article/pii/S0304383517303567?via%3Dihub

5. Tan CC#, Li GX#, Tan LD, Du X, Li XQ, He R, Wang QS, Feng YM*. Breast cancer cells obtain an osteomimetic feature via epithelial-mesenchymal transition that has undergone BMP2/RUNX2 signaling pathway induction.Oncotarget. 2016;7(48):79688-79705.http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=12939&pubmed-linkout=1

6. Li XQ, Lu JT, Tan CC, Wang QS, Feng YM*. RUNX2 promotes breast cancer bone metastasis by increasing integrin α5-mediated colonization.Cancer Lett. 2016;380(1):78-86.https://www.sciencedirect.com/science/article/pii/S0304383516303676?via%3Dihub

7. Cai J#, Tian AX#, Wang QS, Kong PZ, Du X, Li XQ, Feng YM*. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.Cancer Lett. 2015;367(2):129-137.https://www.sciencedirect.com/science/article/pii/S0304383515004358?via%3Dihub

8. Li XQ, Du X, Li DM, Kong PZ, Sun Y, Liu PF, Wang QS, Feng YM*. ITGBL1 Is a Runx2 Transcriptional Target and Promotes Breast Cancer Bone Metastasis by Activating the TGFβ Signaling Pathway.Cancer Res. 2015;75(16):3302-3313.https://cancerres.aacrjournals.org/content/75/16/3302.long

9. Tian HP, Lun SM, Huang HJ, He R, Kong PZ, Wang QS, Li XQ, Feng YM*. DNA Methylation Affects the SP1-regulated Transcription of FOXF2 in Breast Cancer Cells. J Biol Chem. 2015;290(31):19173-19183.http://www.jbc.org/content/290/31/19173.long

10. Wang QS#, Kong PZ#, Li XQ, Yang F, Feng YM*. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer.Breast Cancer Res. 2015;17:30.https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-015-0531-1